Polycystic Ovary Syndrome in Adolescence

June 2008 in “ Annals of the New York Academy of Sciences ”

Susan K. Blank, Kristin D. Helm, Christopher R. McCartney, John C. Marshall

Polycystic Ovary Syndrome PCOS hyperinsulinemia luteinizing hormone LH androgens Hyperandrogenemia HA hirsutism acne menstrual dysfunction metabolic syndrome diabetes infertility oral contraceptive pills insulin sensitizers antiandrogens birth control pills

Studysummary This article proposes a hypothesis that hyperandrogenemia is the final common pathway for developing adolescent PCOS and emphasizes the importance of reducing androgen levels to mitigate risks of metabolic syndrome, diabetes, and infertility in adulthood.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on nyaspubs.onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Polycystic Ovary Syndrome: Early Detection in Adolescents

50 citations , February 2007 in “Clinical obstetrics and gynecology”

This review discusses the clinical manifestations and diagnostic challenges of polycystic ovary syndrome in adolescents, emphasizing the importance of early diagnosis and intervention to manage symptoms effectively, but it reports no new clinical results.

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

research Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

1744 citations , August 2006 in “The Journal of Clinical Endocrinology and Metabolism”

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

research Health Care-Related Economic Burden of Polycystic Ovary Syndrome During the Reproductive Life Span

414 citations , August 2005 in “The Journal of Clinical Endocrinology and Metabolism”

This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.

research Androgen Excess in Women: Experience with Over 1000 Consecutive Patients

947 citations , February 2004 in “The Journal of Clinical Endocrinology and Metabolism”

In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.